Clinical trial NCT06040424: Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
Official title: Randomized, Parallel Group, Phase III, Non-inferiority Study Comparing Ipratropium / Levosalbutamol Fixed Dose Combination in pMDI Form and Ipratropium and Salbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: COPD
Lead sponsor: Neutec Ar-Ge San ve Tic A.Ş
Sponsor class: INDUSTRY
First posted: 2023-09-15
Enrollment: 74
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized, Parallel Group, Phase III, Non-inferiority Study
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to compare the acute bronchodilator effect of pMDI formed Ipratropium / Levosalbutamol 20 mcg / 50 mcg fixed dose combination or pMDI formed Salbutamol 100 mcg Inhaler and Ipratropium 20 mcg Inhalation Aerosol in combination in stable moderate-severe-very severe COPD patients.


Eligibility criteria: Inclusion Criteria:

* Male or female patients aged 40 years and older who have been newly diagnosed or followed up with a diagnosis of COPD.
* Stable moderate-severe-very severe COPD patients with a post-bronchodilator FEV1/FVC ratio \<70% and a postbronchodilator FEV1 value \<80% at the screening visit will be included in the study.
* Symptom status such as chronic cough, sputum production, and progressive dyspnea with the BCSS (Breathlessness, Cough and Sputum Scale) Index will be evaluated, and the COPD staging of the patient with CAT (COPD Assessment Test) and the severity of dyspnea with mMRC (Modified Medical Research Council) will be determined.
* Patients with at least 10 pack/year smoking status or smoking history (patients who have quit smoking for at least 6 months or more are defined as ex-smokers).
* Patients who have not experienced an exacerbation in the previous 4 weeks.
* If the study participant is female; women using appropriate contraception (pregnancy test will be performed at screening visit).
* Patients with the ability to communicate with the investigator.
* Patients who accept to comply with the protocol.
* Patients who sign written informed consent form.

Exclusion Criteria:

* History of hypersensitivity to anticholinergics or SABAs (short acting beta agonist).
* History of COPD exacerbation or lower respiratory track infection that required treatment with antibiotic, oral or parenteral corticosteroid within the last 3 days prior the screening visit or during the run-in/wash-out period or history of respiratory tract infection that required treatment with antibiotic within the last 14 days prior the screening visit.
* Hospitalization due to COPD or pneumonia within the last 3 mounts prior the screening visit.
* SGOT (serum glutamic-oxaloacetic transaminase) \>80 IU/L, SGPT (serum glutamic-pyruvic transaminase) \>80 IU/L, bilirubin \>2.0 mg/dL or creatinine \>2.0 mg/dL.
* History of asthma, significant chronic respiratory diseases (i.e., significant bronchiectasis, interstitial lung diseases, etc.) other than COPD or presence of disease that may be serious and/or potentially affect results of the study.
* Use of beta-blocker, monoamine oxidase (MAO) inhibitor or tricyclic antidepressant within the last 30 days prior the screening visit
* Recent (within ≤3 months prior the screening visit) history of heart attack, heart failure, acute ischemic heart disease or presence of serious cardiac arrhythmia requiring drug treatment.
* Regularly use of daytime CPAP (continuous positive airway pressure) oxygen therapy for longer than 1 hour per day.
* Initiation of pulmonary rehabilitation within the 3 months prior the screening visit.
* History of lung volume reduction surgery
* Drug or alcohol abuse
* Presence of active tuberculosis
* History of atopy or allergic rhinitis
* Presence of active cancer
* Attenuated live virus vaccination within the last 2 weeks prior the screening visit or during the run-in/wash-out period
* Pregnancy or lactation
* Presence of known symptomatic prostatic hypertrophy requiring treatment
* Presence of known narrow-angle glaucoma requiring treatment
* Currently participating in another clinical trial or treatment with another investigational study drug within the last month or 6-half-lives, whichever is longer.

Primary outcomes:
measure: FEV1 area under the curve from 0-8 h (FEV1 AUC 0-8 h)
timeFrame: 8 hours
Secondary outcomes:
measure: FEV1 area under the curve from 0-3 h (FEV1 AUC 0-3 h)
timeFrame: 3 hours
measure: FEV1 AUC 3-6 h
timeFrame: 3 to 6 hours
measure: FEV1 AUC 6-8 h
timeFrame: 6 to 8 hours
measure: FVC AUC 0-3 h
timeFrame: 3 hours
measure: FVC AUC 3-6 h
timeFrame: 3 to 6 hours
measure: FVC AUC 6-8 h
timeFrame: 6 to 8 hours
measure: FVC AUC 0-8 h
timeFrame: 0 to 8 hours
measure: Change From Baseline in FEV1 and FVC within the first 30 minutes after dosing (mL)
timeFrame: Baseline, 30 minutes post-dose at treatment day
measure: Mean Maximum Change From Baseline in FEV1 and FVC within the first 1 hours after dosing (mL)
timeFrame: Baseline, 1 hours post-dose at treatment day
measure: Mean Maximum Change From Baseline in FEV1 and FVC over a period of 8 hours (mL)
timeFrame: Baseline, 0 to 8 hours post-dose at treatment day
measure: The Time to Onset of Bronchodilator Response
timeFrame: Baseline, 0 to 8 hours post-dose at treatment day
measure: Evaluation of Safety
timeFrame: Baseline, 0 to 24 hours post-dose
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital
Study officials:
References: